GlassScriptPhysician profile
Heidi E Houlihan
NPI 1811937683
$5,833.91
in general payments reported to CMS, 2019-2025
25 companies · $3,426 in 2025
The $3,426 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $392 · 2021: $328 · 2022: $428 · 2023: $494 · 2024: $627 · 2025: $3,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,778 · Food and Beverage: $1,744 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,777.50 |
| Food and Beverage | $1,744.23 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $3,189.37 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Contact Lens |
| Glaukos Corporation | $475.39 | 2023-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Abbvie INC. | $291.08 | 2022-2023 | |
| Allergan, INC. | $243.36 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $203.12 | 2019-2021 | |
| Alcon Vision LLC | $199.84 | 2019-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Amgen INC. | $146.90 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $140.82 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $109.88 | 2022-2023 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb Americas INC. | $106.15 | 2022-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Biotissue Holdings INC. | $101.75 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $94.57 | 2020-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $85.84 | 2021-2023 | |
| Maculogix, INC. | $70.01 | 2020-2021 | |
| Horizon Therapeutics Plc | $61.39 | 2021-2023 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $58.58 | 2019-2025 | Oxervate |
| Merz Pharmaceuticals, LLC | $57.52 | 2021-2023 | Xeomin |
| Boston Scientific Corporation | $44.09 | 2024 | Wavewriter Alpha Prime 16 |
| Oyster Point Pharma, INC. | $42.56 | 2024 | Tyrvaya |
| Lkc Technologies, INC. | $24.42 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $22.39 | 2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $21.75 | 2024 | Acthar |
| Thea Pharma INC. | $15.93 | 2023 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.16 | 2020 | |
| Merz North America, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Houlihan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.